Human interleukin-2

Generic Name
Human interleukin-2
Brand Names
-
Drug Type
Biotech
Chemical Formula
-
CAS Number
-
Unique Ingredient Identifier
FNO32LO217
Background

Human interleukin-2 is under investigation in clinical trial NCT03475134 (TIL-ACT After NMA Chemo With IL-2 and Nivo Rescue in mMEL).

Associated Conditions
-
Associated Therapies
-

Phase II Trial of FOLFOXIGIL Versus FOLFOXIRI as First-line Therapy in Patients With mCRC

First Posted Date
2017-07-19
Last Posted Date
2018-03-27
Lead Sponsor
Fujian Cancer Hospital
Registration Number
NCT03222089
Locations
🇨🇳

Rongbo Lin, Fuzhou, Fujian, China

Intraperitoneal Delivery of Adaptive Natural Killer (NK) Cells (FATE-NK100) With Intraperitoneal Int

First Posted Date
2017-07-11
Last Posted Date
2021-03-12
Lead Sponsor
Masonic Cancer Center, University of Minnesota
Target Recruit Count
10
Registration Number
NCT03213964
Locations
🇺🇸

Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States

Adoptive Transfer of iNKT Cells for Treating Patients With Relapsed/Advanced HCC

First Posted Date
2017-06-05
Last Posted Date
2018-01-18
Lead Sponsor
Beijing YouAn Hospital
Target Recruit Count
18
Registration Number
NCT03175679
Locations
🇨🇳

Beijing Youan Hospital,Capital Medical University, Beijing, Beijing, China

Adoptive Transfer of Specific HCC Antigens CD8+ T Cells for Treating Patients With Relapsed/Advanced HCC

First Posted Date
2017-06-05
Last Posted Date
2018-01-18
Lead Sponsor
Beijing YouAn Hospital
Target Recruit Count
18
Registration Number
NCT03175705
Locations
🇨🇳

Beijing Youan Hospital,Capital Medical University, Beijing, Beijing, China

Adoptive Cell Therapy Following a Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Melanoma Patients

First Posted Date
2017-05-25
Last Posted Date
2023-01-26
Lead Sponsor
Sheba Medical Center
Target Recruit Count
30
Registration Number
NCT03166397
Locations
🇮🇱

Sheba Medical Center, Ramat Gan, Israel

Low-dose Interleukin-2 and Pembrolizumab in Melanoma and Renal Cell Cancer

First Posted Date
2017-04-13
Last Posted Date
2019-07-12
Lead Sponsor
William Grosh, MD
Registration Number
NCT03111901
Locations
🇺🇸

University of Virginia Cancer Center, Charlottesville, Virginia, United States

Monitoring of Chimerism After Transplantation in Patients With β Thalassemia Major and the Treatment Strategies for the Reduction of Chimerism

First Posted Date
2017-04-05
Last Posted Date
2018-08-28
Lead Sponsor
First Affiliated Hospital of Guangxi Medical University
Target Recruit Count
30
Registration Number
NCT03101423
Locations
🇨🇳

the First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China

Interleukin-2 Following 4SCAR19/22 T Cells Targeting Refractory and/or Recurrent B Cell Malignancies

First Posted Date
2017-03-31
Last Posted Date
2024-03-18
Lead Sponsor
Zhujiang Hospital
Registration Number
NCT03098355
Locations
🇨🇳

Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong, China

PD-1 Knockout EBV-CTLs for Advanced Stage Epstein-Barr Virus (EBV) Associated Malignancies

First Posted Date
2017-02-07
Last Posted Date
2017-05-02
Lead Sponsor
Yang Yang
Target Recruit Count
20
Registration Number
NCT03044743
Locations
🇨🇳

The Comprehensive Cancer Center of Nanjing Drum Tower Hospital, Nanjing, Jiangsu, China

MIROCALS: Modifying Immune Response and OutComes in ALS

First Posted Date
2017-02-01
Last Posted Date
2022-04-11
Lead Sponsor
Centre Hospitalier Universitaire de Nīmes
Target Recruit Count
304
Registration Number
NCT03039673
Locations
🇫🇷

CHRU de Lille - Hôpital Roger Salengro, Lille, France

🇫🇷

CHU de Limoges - Hôpital Dupuytren, Limoges, France

🇫🇷

HCL - Hôpital Neurologique P. Wertheimer, Lyon, France

and more 14 locations
© Copyright 2024. All Rights Reserved by MedPath